Up to $1M is available from Biomedical Translation Bridge to nurture the translation of new therapies, technologies and medical devices through to the proof of concept stage.
Biomedical Translation Bridge
The Biomedical Translation Bridge program is an initiative of the Medical Research Future Fund, providing up to $1 million in matching funding to help eligible organisations fund and nurture early stage health and medical research to reach proof-of-concept stage with potential to attract further capital and support.
The Biomedical Translation Bridge program supports the ‘Translational Research Infrastructure’ priority identified in the Australian Medical Research and Innovation Priorities 2018-2020.
The funding for the BTB program is drawn from the Fund, and MTP-IIGC LTD trading as MTPConnect, is delivering the program in partnership with BioCurate (University of Melbourne and Monash University), UniQuest (University of Queensland through its drug discovery initiative QEDDI), the Medical Device Partnering Program (MDPP, led by Flinders University) and the Bridge and BridgeTech program (through the Queensland University of Technology).
The BTB program aims to address key national gaps in Australia’s research sector and support three goals:
- Increased commercialisation focus and expertise in early stage research and decision-making across Australia
- Accelerated development, and improved success, of early stage research that has commercial potential so that it can ultimately be commercialised into products and services that improve the health outcomes of Australians as well as contribute to the Australian economy
- Helping to identify existing and new sources of capital investment to bolster awareness and interest in early research investment opportunities.
Research ventures that are successful for funding under the BTB Program will enter into a partnership with MTPConnect and receive up to $1 million over a period of up to two years. Research ventures will be required to provide one-to-one matching funding (cash) to be eligible.
The Biomedical Translation Bridge program will fund:
- Research and development projects to achieve proof-of-concept
- Development to progress novel therapeutics or medical devices. There must be a clear value proposition for the proposed drug candidate or medical device product and differentiating features from currently available solutions.
Commonwealth Funding provided through the BTB program can only be spent on eligible expenditures incurred on eligible activities during the term of the grant and in accordance with the Commonwealth Terms & Conditions for Standard Funding Agreement (March 2015);
Examples of the eligible expenditures include, but are not limited to:
- Salaries and consumables are considered in-kind contributions unless salaries and consumables directly attributed to the delivery of the project outcomes
- Accessing specialist professional services including IP attorney firms, regulatory consultants, manufacturing and product development firms
- Access to and acquisition of specialist equipment, hardware and software
- Accessing or protecting intellectual property rights
- Prototyping and development of a Minimum Viable Product
- Market research/testing and engaging with major customers, and end-users including clinical trials
- Data procurement and efforts to obtain regulatory approval.
To be an eligible organisation you must:
- have an Australian Business Number (ABN)
- be registered for the Goods and Services Tax (GST)
- be incorporated in Australia,
and, in accordance with s24 of the Medical Research Future Fund Act 2015, you must be one of the following eligible bodies:
- a medical research institute
- a university
- a corporate Commonwealth entity
- a corporation (including businesses and not for profits).
Applications close 16 August 2019.